Last reviewed · How we verify
CsA for eye emulsion
At a glance
| Generic name | CsA for eye emulsion |
|---|---|
| Also known as | CsA emulsion |
| Sponsor | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks (PHASE4)
- 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis (PHASE3)
- A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease (PHASE2)
- Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device (PHASE1, PHASE2)
- 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin) (PHASE3)
- Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax (PHASE4)
- Novel Use of Restasis and PROSE Devices (PHASE3)
- Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |